Published in Oncotarget on April 01, 2011
Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle (2011) 1.82
The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma. Virchows Arch (2014) 0.92
PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget (2013) 0.89
Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. Oncotarget (2014) 0.88
Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis. J Cancer Res Clin Oncol (2013) 0.86
EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One (2013) 0.85
Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med (2013) 0.84
Tagging strategies strongly affect the fate of overexpressed caveolin-1. Traffic (2015) 0.83
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma. PLoS One (2014) 0.81
Targeted therapies in sarcomas: challenging the challenge. Sarcoma (2012) 0.80
Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest (2015) 0.77
The potential protective role of caveolin-1 in intestinal inflammation in TNBS-induced murine colitis. PLoS One (2015) 0.77
Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget (2015) 0.77
Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model. Oncotarget (2014) 0.76
Nerve Growth Factor Signaling from Membrane Microdomains to the Nucleus: Differential Regulation by Caveolins. Int J Mol Sci (2017) 0.75
Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis. Oncoscience (2015) 0.75
The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells. Cell Death Dis (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet (1993) 5.00
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Caveolae and caveolins. Curr Opin Cell Biol (1996) 3.25
Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem (1996) 3.05
Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res (1994) 3.02
Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem (1996) 2.95
Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene (1998) 2.59
Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem (2000) 2.56
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem (1997) 2.52
Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol (2009) 2.41
Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. J Cell Biol (2007) 2.31
Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer (1992) 2.31
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell (2003) 2.16
Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J Biol Chem (1999) 1.79
Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell (2003) 1.67
Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res (2006) 1.57
Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol (2001) 1.43
Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch (2009) 1.39
Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem (2004) 1.37
Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol (2004) 1.37
Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene (2004) 1.35
Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med (2008) 1.31
Caveolae at a glance. J Cell Sci (2010) 1.31
Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer (2009) 1.23
Caveats of caveolin-1 in cancer progression. Cancer Lett (2008) 1.21
Molecular and cellular biology of rhabdomyosarcoma. Future Oncol (2009) 1.20
Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep (2010) 1.16
Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene (2003) 1.15
Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res (2007) 1.07
Molecular pathology in sarcomas. Clin Transl Oncol (2007) 1.07
Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther (2009) 1.04
Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res (2006) 1.02
Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize. Mol Cancer Res (2010) 1.01
Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res (2009) 1.00
Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery (2009) 1.00
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res (2004) 0.98
Cavin fever: regulating caveolae. Nat Cell Biol (2009) 0.98
Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer (2010) 0.94
M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett (1996) 0.93
Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol (2003) 0.92
The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol (2010) 0.87
A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models. Appl Immunohistochem Mol Morphol (2010) 0.87
Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur J Cancer (2010) 0.86
Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model. Oligonucleotides (2006) 0.81
Src family kinase-dependent phosphorylation of a 29-kDa caveolin-associated protein. Biochem Biophys Res Commun (2002) 0.80
Caveolin expression is common among benign and malignant smooth muscle and adipocyte neoplasms. Mod Pathol (2002) 0.80
Auto-stimulatory action of secreted caveolin-1 on the proliferation of Ewing's sarcoma cells. Int J Oncol (2011) 0.79
Molecular classification of osteosarcoma. Cancer Treat Res (2009) 0.79
Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma. Appl Immunohistochem Mol Morphol (2005) 0.77
Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res (2006) 1.57
2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res (2011) 1.22
Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene (2003) 1.15
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res (2010) 1.12
Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res (2005) 1.09
Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene (2005) 1.07
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res (2009) 1.04
Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res (2006) 1.02
Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize. Mol Cancer Res (2010) 1.01
PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism. Cancer Res (2007) 0.99
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res (2007) 0.97
Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer (2010) 0.94
The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of rapamycin in the response of normal fibroblasts to ionizing radiation. Cancer Res (2003) 0.93
Brush border myosin Ia has tumor suppressor activity in the intestine. Proc Natl Acad Sci U S A (2012) 0.91
Desmoplastic small round cell tumor 20 years after its discovery. Future Oncol (2015) 0.90
PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res (2009) 0.90
Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem (2012) 0.90
Deregulated expression of the PCPH proto-oncogene in human breast cancers. Int J Oncol (2004) 0.87
Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue. J Med Chem (2009) 0.86
EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One (2013) 0.85
PCPH expression is an early event in the development of testicular germ cell tumors. Int J Oncol (2006) 0.85
Brush border myosin Ia inactivation in gastric but not endometrial tumors. Int J Cancer (2012) 0.82
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin Pharmacother (2015) 0.81
The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma. Int J Oncol (2013) 0.80
Androgen-binding protein and reproduction: where do we stand? J Androl (2002) 0.80
Targeted therapies in sarcomas: challenging the challenge. Sarcoma (2012) 0.80
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma Res (2016) 0.79
Auto-stimulatory action of secreted caveolin-1 on the proliferation of Ewing's sarcoma cells. Int J Oncol (2011) 0.79
Prospects for MEK inhibitors for treating cancer. Expert Opin Drug Saf (2014) 0.77
Estrogen receptor beta expression and apoptosis of spermatocytes of mice overexpressing a rat androgen-binding protein transgene. Biol Reprod (2004) 0.76
Simultaneous KIT mutation and succinate dehydrogenase (SDH) deficiency in a patient with a gastrointestinal stromal tumour and Carney-Stratakis syndrome: a case report. Histopathology (2014) 0.76
Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas? Expert Rev Anticancer Ther (2015) 0.75
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget (2017) 0.75
Laser capture microdissection to assess development. Methods Enzymol (2002) 0.75